Welcome to our dedicated page for Liminatus Pharma news (Ticker: LIMN), a resource for investors and traders seeking the latest updates and insights on Liminatus Pharma stock.
Liminatus Pharma, Inc. (NASDAQ: LIMN) generates news at the intersection of biotechnology, immuno-oncology, capital markets, and emerging digital asset strategies. Public communications describe Liminatus as a clinical-stage and preclinical-stage biopharmaceutical company focused on targeted cancer immunotherapies, including a GCC vaccine candidate for Guanylyl Cyclase C–expressing cancers and a proprietary CD47‑blockade antibody, IBA101, designed for solid tumors.
News coverage for Liminatus often highlights developments in its oncology pipeline and its evolving approach to financing and treasury management. Press releases have detailed a strategic review of blockchain-integrated treasury strategies, exploration of regulated digital asset opportunities, and consideration of a dedicated digital asset investment vehicle. The company has also announced an engagement agreement with Digital Offering LLC as exclusive placement agent for a potential capital raise and an MOU with Capital Trust Group Limited for a proposed equity financing to support research and development of advanced immunotherapy assets.
Investors and observers following LIMN news can expect updates on Nasdaq listing compliance notices disclosed in Form 8‑K filings, including notices related to delayed periodic reports and market value listing standards. Additional news items describe Liminatus’s intention to form a subsidiary called "American BNB Strategy" to pursue long-term BNB coin investments, subject to regulatory and corporate approvals, while the company reiterates its core focus on cancer therapeutics and diagnostics.
This news page aggregates such company-issued announcements and regulatory-related developments so readers can review how Liminatus communicates progress on its immuno-oncology programs, capital formation efforts, and digital asset-linked treasury strategies over time.
Liminatus Pharma (NASDAQ: LIMN) priced a best-efforts public offering of 13,813,000 common shares (or pre-funded warrants) and warrants to purchase 20,719,500 shares at a combined public offering price of $0.29 per share on February 17, 2026.
Gross proceeds are expected to be approximately $4.0 million, with potential additional proceeds of about $6.0 million if warrants are fully exercised; closing expected on or about February 18, 2026.
Liminatus Pharma (NASDAQ: LIMN) signed a Memorandum of Understanding with Capital Trust Group for a USD 30,000,000 equity financing via an earn-out mechanism to support R&D of its immuno-oncology programs. The investment is subject to due diligence, negotiation of definitive agreements, Nasdaq and U.S. securities compliance, and effectiveness of a registration statement for resale of the shares. Both parties target execution of definitive agreements in November 2025 and plan to discuss further strategic cooperation beginning mid-November, including potential digital bond financing programs.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, announced plans to establish "American BNB Strategy," a subsidiary focused on cryptocurrency investments. The company aims to raise and deploy up to $500 million for strategic, long-term investments in BNB coin, the native token of the Binance ecosystem.
While maintaining its core focus on cancer therapeutics and diagnostics, Liminatus views this expansion into digital assets as crucial for long-term growth. The company plans to utilize Ceffu's custody infrastructure for institutional-grade security and is currently working with Digital Offering on the capital raise process, pending regulatory clearance and market conditions.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company, has initiated a strategic review to explore forming a digital asset investment subsidiary. The company is evaluating options to target up to $500 million in capital formation through various financing tools.
The proposed subsidiary would focus on digital asset allocation and blockchain-integrated financial structures, operating independently from Liminatus's core clinical pipeline. Currently, no capital has been raised or committed, no agreements executed, and no partnerships established. The initiative remains subject to Board approval, regulatory compliance, and market conditions.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has engaged Digital Offering LLC as its exclusive placement agent to evaluate potential strategic capital raising options.
The engagement supports Liminatus's exploration of a digital asset treasury strategy and may include various financing structures such as convertible debentures, equity-linked securities, or alternative instruments. Digital Offering will help source institutional and digital asset-focused investors while ensuring regulatory compliance.
CEO Chris Kim emphasized that while no financing transaction has been finalized, this partnership allows the company to explore both traditional and digital asset funding opportunities strategically.
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced the initiation of a strategic review to evaluate potential blockchain and digital asset integration into its treasury management strategy.
While maintaining its primary focus on cancer therapy development, the company is exploring regulated digital asset opportunities to optimize its balance sheet and enhance treasury efficiency for non-operating capital reserves. CEO Chris Kim emphasized that this exploratory process does not represent a shift in business focus and any future implementation would require Board approval and SEC compliance.